ATE284712T1 - Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide - Google Patents

Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide

Info

Publication number
ATE284712T1
ATE284712T1 AT01925974T AT01925974T ATE284712T1 AT E284712 T1 ATE284712 T1 AT E284712T1 AT 01925974 T AT01925974 T AT 01925974T AT 01925974 T AT01925974 T AT 01925974T AT E284712 T1 ATE284712 T1 AT E284712T1
Authority
AT
Austria
Prior art keywords
adenosine
defecation
receptor antagonists
activation
medicinal compositions
Prior art date
Application number
AT01925974T
Other languages
English (en)
Inventor
Masahiro Yasuda
Hitoshi Harada
Shuhei Miyazawa
Seiichi Kobayashi
Kokichi Harada
Takayuki Hida
Hisashi Shibata
Nobuyuki Yasuda
Osamu Asano
Yoshihiko Kotake
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE284712T1 publication Critical patent/ATE284712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B10/00—Transmission systems employing electromagnetic waves other than radio-waves, e.g. infrared, visible or ultraviolet light, or employing corpuscular radiation, e.g. quantum communication
    • H04B10/11—Arrangements specific to free-space transmission, i.e. transmission through air or vacuum
    • H04B10/112—Line-of-sight transmission over an extended range

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Electromagnetism (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT01925974T 2000-04-26 2001-04-26 Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide ATE284712T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000126489 2000-04-26
JP2000220124 2000-07-21
PCT/JP2001/003643 WO2001080893A1 (fr) 2000-04-26 2001-04-26 Compositions medicinales favorisant les mouvements intestinaux

Publications (1)

Publication Number Publication Date
ATE284712T1 true ATE284712T1 (de) 2005-01-15

Family

ID=26590887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925974T ATE284712T1 (de) 2000-04-26 2001-04-26 Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide

Country Status (16)

Country Link
US (3) US7189717B2 (de)
EP (2) EP1510222A3 (de)
JP (1) JP4128360B2 (de)
KR (2) KR100782091B1 (de)
CN (1) CN1197621C (de)
AT (1) ATE284712T1 (de)
AU (2) AU5260601A (de)
CA (1) CA2407013A1 (de)
DE (1) DE60107835T2 (de)
HU (1) HUP0300927A2 (de)
IL (2) IL152023A0 (de)
MX (1) MXPA02010552A (de)
NO (1) NO20025116L (de)
NZ (1) NZ521633A (de)
RU (2) RU2294762C2 (de)
WO (1) WO2001080893A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521633A (en) 2000-04-26 2005-01-28 Eisai Co Ltd Use of an adenosine A2 or A2b recpetor antagonist for promoting bowel movement
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (de) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
ES2716404T3 (es) 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
AU2003216585A1 (en) * 2002-04-10 2003-10-20 Orchid Chemicals And Pharmaceuticals Limited Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
BRPI0417478A (pt) * 2003-12-15 2007-05-08 Almirall Prodesfarma Ag 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
SE0400233D0 (sv) * 2004-02-04 2004-02-04 Ltp Lipid Technologies Provide Rektal komposition
CA2561383A1 (en) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Prophylactic and/or therapeutic agents for chronic musculoskeletal pain
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
EP1888565B1 (de) * 2005-04-11 2011-03-23 Almirall, S.A. 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
JP2008536950A (ja) * 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
FR2902010B1 (fr) * 2006-06-12 2008-08-22 Pierre Fabre Medicament Sa Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
US20080009623A1 (en) * 2006-07-06 2008-01-10 Eisai R&D Management Co., Ltd. Pyrimidine compounds
US8227027B2 (en) * 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
CA2718983C (en) 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
JP5426156B2 (ja) * 2008-12-25 2014-02-26 フマキラー株式会社 排便促進用組成物
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
EP2499142B1 (de) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituierte kondensierte pyrimidinverbindungen, ihre herstellung und ihre verwendung
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
CN103958502B (zh) 2011-08-04 2016-02-10 阵列生物制药公司 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
CA3132120C (en) 2012-02-08 2023-10-24 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CA2866086C (en) 2012-03-01 2020-06-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
CN105143200B (zh) 2012-08-27 2018-10-16 阵列生物制药公司 用于治疗过度增殖性疾病的丝氨酸/苏氨酸激酶抑制剂
ES2580702B1 (es) * 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
JP2017149663A (ja) * 2016-02-24 2017-08-31 株式会社Ｌｔｔバイオファーマ 過敏性腸症候群治療剤
CN105687225B (zh) * 2016-02-26 2018-07-06 四川好医生攀西药业有限责任公司 一种治疗肠易激综合征的药物组合物及其制备方法和应用
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 化合物および組成物ならびにそれらの使用
MX2019000980A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
WO2019121374A1 (en) * 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
EP3820474A4 (de) * 2018-07-10 2022-03-23 Nikang Therapeutics, Inc. Adenosinrezeptorbindende verbindungen
WO2020083957A1 (en) * 2018-10-24 2020-04-30 Leadxpro Ag Functionalized aminotriazines
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
US4673680A (en) 1985-09-18 1987-06-16 Pendleton Robert G α2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
JPH04271770A (ja) * 1991-02-27 1992-09-28 Asahi:Kk お茶
JP3343965B2 (ja) * 1992-10-31 2002-11-11 ソニー株式会社 音声符号化方法及び復号化方法
CN1088053A (zh) * 1993-01-04 1994-06-22 谷中村 一种益寿保健茶叶
JPH06211669A (ja) 1993-01-14 1994-08-02 Kyowa Hakko Kogyo Co Ltd 腸運動の異常亢進治療剤
WO1994016702A1 (en) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
JP3123286B2 (ja) * 1993-02-18 2001-01-09 ソニー株式会社 ディジタル信号処理装置又は方法、及び記録媒体
GB9309573D0 (en) * 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
JP3277679B2 (ja) * 1994-04-15 2002-04-22 ソニー株式会社 高能率符号化方法と高能率符号化装置及び高能率復号化方法と高能率復号化装置
EP0888335A4 (de) * 1996-03-13 2002-01-02 Smithkline Beecham Corp Neue pyrimidinverbindungen und ihre anwendung in der behandlung, von cytokinin-vermittler krankheiten
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO1998024780A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
ATE242775T1 (de) * 1998-01-05 2003-06-15 Eisai Co Ltd Purinderivate und antagonisten des adenosin-a2- rezeptors, welche zur vorsorge oder heilung von diabetes dienen
JP3990061B2 (ja) 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
CA2239294A1 (en) * 1998-05-29 1999-11-29 Majid Foodeei Methods and apparatus for efficient quantization of gain parameters in glpas speech coders
AR020590A1 (es) 1998-06-02 2002-05-22 Cadus Pharmaceutical Corp 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
AU4506399A (en) * 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
KR20010071591A (ko) 1998-06-23 2001-07-28 그레이엄 브레레톤, 레슬리 에드워즈 2-(퓨린-9-일)-테트라히드로푸란-3,4-디올 유도체
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
AUPP672198A0 (en) 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
FR2791167B1 (fr) * 1999-03-17 2003-01-10 Matra Nortel Communications Procedes de codage, de decodage et de transcodage audio
CA2376835C (en) 1999-07-02 2009-09-15 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU2001248365A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
EP1136486A1 (de) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Indanylamino)pyrimidon und 2-(Tetrahydronaphtalenylamino)pyrimidinon Derivate
EP1136482A1 (de) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer
NZ521633A (en) 2000-04-26 2005-01-28 Eisai Co Ltd Use of an adenosine A2 or A2b recpetor antagonist for promoting bowel movement

Also Published As

Publication number Publication date
AU5260601A (en) 2001-11-07
CA2407013A1 (en) 2002-10-22
US20070054876A1 (en) 2007-03-08
NZ521633A (en) 2005-01-28
RU2294762C2 (ru) 2007-03-10
JP4128360B2 (ja) 2008-07-30
NO20025116L (no) 2002-12-23
MXPA02010552A (es) 2003-03-10
NO20025116D0 (no) 2002-10-24
KR100782091B1 (ko) 2007-12-04
HUP0300927A2 (hu) 2003-07-28
IL152023A0 (en) 2003-04-10
DE60107835T2 (de) 2005-12-22
EP1283056A4 (de) 2003-07-02
EP1510222A2 (de) 2005-03-02
WO2001080893A1 (fr) 2001-11-01
KR20020089495A (ko) 2002-11-29
DE60107835D1 (de) 2005-01-20
US20030171383A1 (en) 2003-09-11
RU2005127415A (ru) 2007-03-10
EP1510222A3 (de) 2007-05-23
EP1283056A1 (de) 2003-02-12
AU2001252606B2 (en) 2005-07-07
RU2002131637A (ru) 2004-03-27
US7189717B2 (en) 2007-03-13
US20060270674A1 (en) 2006-11-30
KR20070058022A (ko) 2007-06-07
EP1283056B1 (de) 2004-12-15
CN1197621C (zh) 2005-04-20
CN1426310A (zh) 2003-06-25
IL188052A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
ATE284712T1 (de) Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide
ES2172592T3 (es) Agente antagonista de progesterona y agente gestageno para el tratamiento de la endometriosis y del liomioma uterino.
ATE182078T1 (de) Laxiermittel das ballastfasern und dioctyl- sulfosuccinat enthält
CA2321523A1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
BR9509019B1 (pt) comprimido isento de solventes orgÂnicos.
HU9602668D0 (en) Progesterone antagonists useful preparing medicaments for treating dysfunctional uterine bleeding
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DE69932510D1 (de) Vaskularisierungsinhibitoren
CA2408537A1 (en) Treating irritable bowel syndrome or disease
IS4553A (is) Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara
RU2210573C2 (ru) Углеводные производные
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
NZ514696A (en) IL-8 receptor antagonists
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
MD1473F2 (en) Antiherpetic remedy
KR960023048A (ko) 돼지 유행성 설사병 예방약 생산을 위한 약독화 바이러스주
BR9507848A (pt) Composição farmcéutica contendo espiramicina eventualmente em associação com o metronizadol
NZ515232A (en) IL-8 receptor antagonists
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
UA37427A (uk) Пристрій для очищення прямої кишки
ES2172818T3 (es) Uso de antagonistas de lh-rh como agente de diagnostico.
BR9903472A (pt) Proceso de obtenção das ligninas tetraidrofurânicas veraguensina (1) e grandisina (2), atividade antichagásica e seu uso como anthichagásico
程秋云 et al. Remission of Abdominal Colic During Enteroscopy by Injecting Vitamin K_3 into Zusanli Acupoint
ATE318612T1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie
UA34129A (uk) Антидіарейний засіб "силоглюкан"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties